admilparant — Topline data
early 2027
Admilparant is also being studied in the fully enrolled Phase 3 ALOFT-PPF trial in progressive pulmonary fibrosis (PPF), with topline results anticipated in early 2027.Source filing
BMY biotech catalysts & pipeline
BRISTOL MYERS SQUIBB CO · Data as of 2026-10-25
Upcoming catalysts
luspatercept — PDUFA
Mar 11
The FDA granted a Prescription Drug User Fee Act (PDUFA) date of March 11, 2027.Source filing
mezigdomide — PDUFA
May 13
The FDA accepted a New Drug Application for mezigdomide in combination with carfilzomib and dexamethasone (MeziKd) in patients with relapsed or refractory multiple myeloma (RRMM), granting a PDUFA date of May 13, 2027.Source filing
ZENBEXUS™ (iberdomide) — Conference presentation
Dec 12–Dec 15
This data will be presented at the 68th Annual Meeting of the American Society of Hematology in New Orleans, L.A.Source filing